DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story

starstarstarstarstar (2)
Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Molecular Imaging Homepage

GE to provide training to at least 140 Kenyan radiographers Partnering with Society of Radiography in Kenya

NorthStar, Shine in line for federal funding Bringing $20 million in additional funding to domestic moly-99 in the US

Adel Abdullah and Aaron Hargrave Positron appoints president and vice president

Theranostics – Nuclear medicine´s fountain of youth Combining therapeutics with diagnostics, opportunities and challenges

Cerveau Technologies partners with Ionis Pharmaceuticals Use of PET agent, [F-18]MK-6240

New PET imaging method may yield benefits over FDG for detecting certain cancers Gallium-68-labeled FAPI tracer yields promising results

Dr. David Wong Professor recognized for contributions to PET and Theranostics

SVSR unveils Siemens Horizon PET/CT trailer Putting a small and powerful scanner on a coach

Philips to manage medical imaging equipment for Aussie providers for 20 years First-of-its-kind partnership in Australia and ASEAN Pacific region

Under AMG, Piramal Imaging changes name to Life Molecular Imaging LMI is being run within the Alliance Medical Molecular Imaging division

Congress to evaluate bill to reclassify
radiopharmaceuticals in Medicare
outpatient-based settings

New House bill calls for change in CMS definition of radiopharmaceuticals

by John R. Fischer , Staff Reporter
A new bill is calling for CMS to recognize diagnostic radiopharmaceuticals as drugs under the Medicare Hospital Outpatient Prospective Payment System, to spare hospitals the financial burdens associated with their current classification as supplies.

Introduced late last month by congressmen George Holding (R.-NC) and Seth Moulton (D.-MA) in the U.S. House of Representatives, the Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018 seeks to change the status of radiopharmaceuticals so that they may be paid for separately in Medicare hospital outpatient settings rather than as bundled payments.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



“Supplies are considered ancillary to a procedure in the Medicare hospital outpatient setting, and therefore payment is packaged into the payment for the scan,” Patrick Hope, executive director of the Medical Imaging & Technology Alliance (MITA), told HCB News. “The current CMS averaging system packages lower-volume, higher-cost diagnostic radiopharmaceuticals with other higher-volume, lower-cost drugs. In some instances, the cost of the diagnostic radiopharmaceutical exceeds the entire packaged amount of reimbursement, creating the potential for hospitals to lose money every time they perform the procedure.”

As a result of these difficulties, many small providers are hesitant to perform certain exams, such as an Octreoscan procedure to visualize hormone-producing tumors in the nervous and endocrine systems. The cost of this procedure ranges from $1,200 to 1,400 with reimbursement nowhere near that amount, causing patients in need of it to seek help from bigger, far away facilities.

In addition, including radiopharmaceuticals as a bundled payment also deters research and innovation, with companies less inclined to spend money on development for such compounds due to providers unwilling to purchase them.

Hope says the passage of H.R. 6948 would open up access for patients to necessary diagnostic exams for a variety of diseases, including cancer, neurologic, and cardiac conditions, improving diagnostic accuracy and enabling physicians to develop treatments that avoid unnecessary procedures.

He also points out that doing so would eliminate inconsistencies in CMS’ definition of diagnostic radiopharmaceuticals, which depends on the site of care, with freestanding, non-hospital based imaging centers recognizing them as drugs and paid for as such by CMS, in contrast to hospital-based outpatient settings.

“These drugs go through the rigor of the FDA approval process and should therefore be considered the same as other drugs,” he said, adding that the FDA regulates radiopharmaceuticals as drugs. “Paying separately at a $500 drug threshold will provide more appropriate reimbursement, ensure patients have access to vital diagnostic tests, and allow for continued innovation in molecular imaging.”

Whether or not the bill will pass in the coming months is “hard to say”, according to Hope, due to the end of the year approaching and “uncertainty” over the outcome of the midterm elections.

MITA, however, plans to work with other stakeholders to ensure the bill does become law.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED